Post Profile






Lilly's stomach cancer drug meets main goal, but fails to improve survival rate

(Reuters) - Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates.
read more

share
See more about: Eli Lilly

Related Posts


Lilly migraine treatment meets main goal in late-stage studies

Health : Reuters: Health

(Reuters) - Eli Lilly and Co said on Friday its experimental treatment met the main goal of reducing the number of monthly migraine headache days compared to a placebo in three late-stage studies.

Lilly reports positive interim data on breast cancer combo drug

Health : Reuters: Health

(Reuters) - Eli Lilly and Co said the combination of its experimental breast cancer drug and a commonly used treatment met the main goal of a late-stage study in an interim analysis, setting the stage for a regulatory submission lat...

Lilly's lung cancer drug fails late-stage study

Health : Reuters: Health

(Reuters) - Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study.

Lilly's breast cancer drug fails to help lung patients

Health : Reuters: Health

(Reuters) - Eli Lilly and Co said its recently approved breast cancer drug failed to meet a late-stage trial's main goal of improving overall survival in patients with non-small cell lung cancer.

Lilly's lung cancer drug fails main goal of key study

Health : Reuters: Health

(Reuters) - Eli Lilly and Co said its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage trial, sending its shares down about 3 percent.

Comments


Copyright © 2016 Regator, LLC